PHARM.ASPHARM.ASAMS
Loading
EPS Growth Under PressureDecelerating
Percentile Rank74
5Y CAGR+53.8%
Year-over-Year Change
Year-over-year earnings per share growth rate
5Y CAGR
+53.8%/yr
Long-term compound
Percentile
P74
Within normal range
vs 5Y Ago
8.6x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 61.43% |
| Q2 2025 | 131.82% |
| Q1 2025 | -558.33% |
| Q4 2024 | 400.00% |
| Q3 2024 | -12.99% |
| Q2 2024 | 90.68% |
| Q1 2024 | -367.98% |
| Q4 2023 | -177.33% |
| Q3 2023 | 162.50% |
| Q2 2023 | 110.53% |
| Q1 2023 | 13.64% |
| Q4 2022 | -257.14% |
| Q3 2022 | -39.13% |
| Q2 2022 | 360.00% |
| Q1 2022 | 72.41% |
| Q4 2021 | 0.00% |
| Q2 2021 | -41.85% |
| Q1 2021 | -23.53% |
| Q4 2020 | 41.67% |
| Q3 2020 | -20.00% |
| Q2 2020 | 7.14% |
| Q1 2020 | -26.32% |
| Q4 2019 | 18.75% |
| Q3 2019 | 45.45% |
| Q2 2019 | -8.33% |
| Q1 2019 | -45.45% |
| Q4 2018 | 151.43% |
| Q3 2018 | 60.26% |
| Q2 2018 | -18.75% |
| Q1 2018 | 107.23% |
| Q4 2017 | -416.67% |
| Q3 2017 | 69.49% |
| Q2 2017 | -353.85% |
| Q1 2017 | 7.14% |
| Q4 2016 | -58.91% |
| Q3 2016 | -2.80% |
| Q2 2016 | 5.51% |
| Q1 2016 | 9.03% |
| Q4 2015 | -55.78% |
| Q3 2015 | -6.49% |